Novo Nordisk stock gets drilled on pipeline concerns— its CEO sees this as the main problem

Shares of Novo Nordisk experienced a significant drop of over 4% on Monday due to Wall Street's dissatisfaction with the company's lack of detailed growth targets during its capital markets day. The pharmaceutical giant aims to generate more than $23 billion in pipeline sales by 2035, with plans to launch over five potential multi-blockbusters by the end of the decade.

Novo Nordisk CEO Mike Doustdar acknowledged the fierce competition in the weight-loss drug market, stating that the company has created an attractive market and now faces intense competition from rival pharma companies. Since becoming CEO in August 2025, Doustdar has been focused on improving Wegovy marketing, building momentum behind its pill form, and investing more aggressively in R&D to overcome future patent expirations.

He expressed the need to improve Wegovy sales and continue building momentum while investing in R&D to address patent expirations and ensure Novo Nordisk maintains a dominant position in the market.